Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Sintx Technologies, led by CTO Ryan Bock, has achieved FDA clearance and collaborated with a research group at Virginia Tech.

2 reports, 1 independent Updated Sep 3
Gone quiet
Reports
2
Developments
3
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Sintx Technologies, led by CTO Ryan Bock, has achieved FDA clearance and collaborated with a research group at Virginia Tech.

Who's involved

What this event is mainly about
FDA

How it developed

Newest first. Tap a step to see who reported it.
  1. Sintx Technologies submitted a 510(k) premarket notification to the FDA on July 22, 2025.Sub-event
  2. Sintx Technologies is an FDA-cleared manufacturer that collaborated with Virginia Tech.1 source
  3. NIH provided support for a research study conducted by Sintx Technologies.1 source

Keep exploring

Part of

A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Also in this story

All 83 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • GlobeNewswireSINTX Technologies Publishes Landmark Study Demonstrating Broad-Spectrum Antiviral Activity of Silicon Nitride Breakthrough findings open doors to multi-billion-dollar infection-control markets SALT
  • GlobeNewswireSINTX Technologies Expands Silicon Nitride Platform into Hybrid CFR-PEKK Trauma Plates SALT LAKE CITY, Utah, Aug. 04, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the